Cellectar Biosciences, Inc. (CLRB) Earnings History
Annual and quarterly earnings data from 2004 to 2025
Loading earnings history...
CLRB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CLRB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CLRB earnings history in CSV or JSON format
Free sign-in required to download data
Cellectar Biosciences, Inc. (CLRB) Earnings Overview
As of May 8, 2026, Cellectar Biosciences, Inc. (CLRB) reported trailing twelve-month net income of -$22M, reflecting +80.1% year-over-year growth. The company earned $-5.14 per diluted share over the past four quarters.
Looking at the long-term picture, CLRB's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2010.
Cellectar Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRTC (-$56M net income, -2355.4% margin), RNAC (-$152M net income, -4658.6% margin), RMD ($1.52B net income, 27.2% margin), CLRB has comparable earnings metrics. Compare CLRB vs PRTC →
CLRB Earnings vs Peers
Earnings metrics vs comparable public companies
CLRB Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$22M | +51.1% | -$23M | $-8.35 | - | - |
| 2024 | -$45M | -4.2% | -$52M | $-41.89 | - | - |
| 2023 | -$43M | -34.5% | -$39M | $-104.99 | - | - |
| 2022 | -$32M | -31.8% | -$29M | $-135.18 | - | - |
| 2021 | -$24M | -59.8% | -$24M | $-130.35 | - | - |
| 2020 | -$15M | -7.1% | -$15M | $-228.55 | - | - |
| 2019 | -$14M | -6.4% | -$14M | $-550.86 | - | - |
| 2018 | -$13M | +2.4% | -$13M | $-1567.96 | - | - |
| 2017 | -$14M | -119.4% | -$14M | $-3210.00 | - | - |
| 2016 | -$6M | -12.5% | -$9M | $-6420.00 | - | - |
See CLRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLRB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLRB — Frequently Asked Questions
Quick answers to the most common questions about buying CLRB stock.
Is CLRB growing earnings?
CLRB EPS is $-5.14, with earnings growth accelerating to +80.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-22M.
What are CLRB's profit margins?
Cellectar Biosciences, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CLRB's earnings?
CLRB earnings data spans 2004-2025. The accelerating earnings trend is +80.1% YoY. Historical data enables comparison across business cycles.